0000000000427778

AUTHOR

Yan Valle

0000-0002-9340-9045

showing 2 related works from this author

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

2020

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items…

medicine.medical_specialtybusiness.industryVitiligoMEDLINETreatment optionsDermatologyGeneral MedicineVitiligomedicine.diseaselaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030220 oncology & carcinogenesisQuality of LifemedicineHumansImmunologic FactorsProspective StudiesIntensive care medicinebusinessPUVA TherapyDermatologic Therapy
researchProduct

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct